Investor Overview

Webcast ImageWebcast
Aimmune Therapeutics at the 2017 Wedbush PacGrow Healthcare Conference (Replay)
08/16/17 at 9:45 a.m. ET
Aimmune Therapeutics at the 2017 Wedbush PacGrow Healthcare Conference
Wednesday, August 16, 2017 9:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >
Recent Newsmore >
August 9, 2017
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 16, at 9:45 a.m. Eastern Time. The live webcast of the presentation will be accessible on the Events page und... 
August 8, 2017
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California--(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017. As of June 30, 2017, cash, cash equivalents, and investments totaled $237.3 million. “During the second quarter, Aimmune continued to make significant progress in our Phase 3... 
August 8, 2017
Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
— Discovery of TH2A Cells by Benaroya Research Institute Scientists, Led by Erik Wambre, Ph.D., Could Focus Future Allergy Research — — AR101 Treatment Linked to Decrease in TH2A Cells in Samples from Peanut-Allergic Patients from ARC001 Trial — BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today a... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.